E4BP4 promotes MM progression by upregulating HDAC3, reducing histone acetylation and Beclin1 transcription to suppress autophagy/apoptosis. Its role in dexamethasone resistance highlights E4BP4 as a potential therapeutic target.

Stereotactic brain biopsy confirmed PCNSL, and the patient was initiated on high-dose methotrexate-based chemotherapy with adjunctive dexamethasone. This case highlights that PCNSL can occur despite immunologic preservation in HIV and may present acutely with seizures. Early contrast-enhanced MRI, careful timing of corticosteroid use relative to biopsy, and timely referral are essential, particularly in resource-limited settings.

P=N/A, N=65, Not yet recruiting, University of California, Davis

Further, to establish mAb ASGPR1-mediated drug delivery, an anti-inflammatory drug dexamethasone (DEX) was conjugated to mAb ASGPR1 through an ester linker generating mAb ASGPR1-DEX ADC...The mAb ASGPR1-DEX conjugate exhibited significant efficacy against lipopolysaccharide-induced hepatic inflammation by attenuating levels of interleukin-6, interleukin-1beta, and tumor necrosis factor in mouse precision cut liver slices and hepatocyte organoids. Collectively, these findings hold significant implications for mAb ASGPR1-based ADC as a promising therapeutic modality that warrants further investigation in inflammation-induced liver pathologies.

This study presents a long-acting hybrid dissolving microneedle (DMN) patch incorporating hyaluronic acid (HA)-based microparticle depots (TA@MDepots) for intradermal delivery of triamcinolone acetonide (TA)...Histological analyses confirm skin structure restoration and immune modulation, while systemic toxicity assessments show no adverse effects. This hybrid DMN platform offers a minimally invasive, biocompatible, and patient-friendly strategy for prolonged corticosteroid delivery in chronic inflammatory skin diseases and represents a promising alternative to conventional topical or injectable therapies.

P4, N=1, Terminated, Weill Medical College of Cornell University | Active, not recruiting --> Terminated; The study was terminated due to slow accrual.

P=N/A, N=200, Recruiting, Chulalongkorn University | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Nov 2026

P3, N=276, Recruiting, Erasmus Medical Center

Pretreatment CD4+ T-cell levels were identified as a prognostic PFS marker. In summary, our results demonstrate significant effects of cycloaddition to Pd on response and T-cell composition.

Our study demonstrated that chronic glucocorticoid-induced stress altered the epigenetic profile of tumor cells by in- ducing differential methylation of the matrix metalloproteinase genes. Specifi  ally, it promoted the maintenance of Mmp1 hypomethylation and signifi  antly increased the Mmp8 promoter hypermethylation. These fi  dings suggest that chronic stress may contribute to an aggressive tumor phenotype through the epigenetic regulation of extracel- lular matrix remodeling.

This case highlights the diagnostic challenges of antibody-negative paraneoplastic neurologic syndromes. The study underscores the important role of PET-CT in identifying occult malignancy and the role of repeat biopsy in progressive disease. Discordant histologic findings should be interpreted cautiously, as they may reflect tumor heterogeneity or possible adenosquamous carcinoma rather than true histologic evolution. Limited molecular testing, and sampling constraints remain important challenges, particularly in resource-limited settings.

P2, N=384, Active, not recruiting, The University of Queensland | Recruiting --> Active, not recruiting